Halozyme Therapeutics, Inc. (HALO) stock surged +1.09%, trading at $57.39 on NASDAQ, up from the previous close of $56.77. The stock opened at $57.05, fluctuating between $56.60 and $57.45 in the recent session.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Employees | 373 |
Beta | 1.29 |
Sales or Revenue | $829.25M |
5Y Sales Change% | 4.937% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock price is $57.39 in the last trading session. During the trading session, HALO stock reached the peak price of $57.45 while $56.60 was the lowest point it dropped to. The percentage change in HALO stock occurred in the recent session was 1.09% while the dollar amount for the price change in HALO stock was $0.62.
The NASDAQ listed HALO is part of Biotechnology industry that operates in the broader Healthcare sector. Halozyme Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Gary Grote
Chief Commercial Officer
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Pres, Chief Executive Officer & Director
Dr. Christopher Bryant Ph.D.
Chief Manufacturing Officer & Head of Technical Operations
Dr. Michael J. LaBarre Ph.D.
Senior Vice President & Chief Technical Officer
Dr. Steve Knowles MBBS
Chief Medical Officer
Mr. Todd Butler
Chief of Staff to the Chief Executive Officer, Vice President & Head of Project Management
Ms. Amy Marinne Fox
Chief HR Officer
Ms. Nicole LaBrosse
Senior Vice President & Chief Financial Officer
Mr. Mark Snyder Esq.
Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Ms. Tram Bui
Head of Investor Relations & Corporation Communications
Ms. Kristin Schwartzbauer
Head of Quality
HALO's closing price is 68.76% higher than its 52-week low of $34.36 where as its distance from 52-week high of $65.53 is -13.37%.
Number of HALO employees currently stands at 373.
Official Website of HALO is: https://www.halozyme.com
HALO could be contacted at phone 858 794 8889 and can also be accessed through its website. HALO operates from 11388 Sorrento Valley Road, San Diego, CA 92121, United States.
HALO stock volume for the day was 433.19K shares. The average number of HALO shares traded daily for last 3 months was 1.66M.
The market value of HALO currently stands at $7.30B with its latest stock price at $57.39 and 127.23M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com